Description: Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
Home Page: www.ascelia.com
Hyllie Boulevard 34
Malmö,
215 32
Sweden
Phone:
46 735 179 118
Officers
| Name | Title |
|---|---|
| Mr. Magnus O. Corfitzen | Chief Exec. Officer |
| Ms. Despina Georgiadou Hedin | Chief Financial Officer |
| Mr. Andreas Norlin | Chief Scientific Officer |
| Mr. Mikael Widell | Head of IR & Communications |
| Dr. Carl Bjartmar M.D., Ph.D. | Chief Medical Officer |
| Ms. Julie Waras Brogren | Deputy CEO & Chief Commercial Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3391 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |